5 completed, 3 recruiting, 1 withdrawn. 9 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 9 | Completed 5, Recruiting 3, Withdrawn 1 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined Tagraxofusp, Pacritinib - Myelofibrosis，MF | Early Phase 1 | Recruiting | University of Kansas Medical Center | 20 | 2025-08-25 | 2026-05-06 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant Hyperbaric oxygen - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Omar Aljitawi | 24 | 2020-07-01 | 2026-06-03 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Primary Myelofibrosis, Secondary Myelofibrosis | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2018-01-31 | 2020-10-14 |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Bone Marrow Aspiration and Biopsy, Laboratory Biomarker Analysis, Siltuximab - Myelofibrosis, Polycythemia Vera | Early Phase 1 | Withdrawn | Northwestern University | 2016-06-01 | 2016-10-24 | |
| Intra-Osseous Co-Transplant of UCB and hMSC cyclophosphamide, fludarabine phosphate, total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 6 | 2015-07-22 | 2020-12-04 |
| Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis arsenic trioxide, cytarabine - Myelofibrosis | Early Phase 1 | Completed | Weill Medical College of Cornell University | 21 | 2008-02-29 | 2017-03-03 |
| Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases Pemetrexed - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Early Phase 1 | Completed | Northwestern University | 15 | 2007-01-01 | 2021-09-08 |
| Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders PS-341 - Chronic Myeloproliferative Disorders, Leukemia | Early Phase 1 | Completed | Mayo Clinic | 30 | 2005-09-01 | 2014-10-17 |
Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (4) · Hodgkin Disease (3) · Leukemia, Myelomonocytic, Chronic (3) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Lymphoma (2) · Lymphoma, Follicular (2) · Multiple Myeloma (2) · Myeloproliferative Disorders (2)
Bone Marrow Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Myeloproliferative Disorders (7) · Neoplasms by Histologic Type (6) · Chronic Disease (5) · Disease Attributes (5) · Neoplasms (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia, Myeloid (4) · Lymphatic Diseases (4) · Leukemia (3)
Cyclophosphamide (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Arsenic Trioxide (1) · Biopsy (1) · Bortezomib (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Cytarabine (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Hematopoietic Stem Cell Transplantation (1) · Hyperbaric Oxygenation (1)
Northwestern University (2) · Case Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Omar Aljitawi (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Kansas Medical Center (1) · Weill Medical College of Cornell University (1)
United States (8)
Abdulraheem Yacoub, Doctor of Medicine (1) · Brady Stein, MD (1) · Candido E. Rivera, M.D. (1) · Christian B Gocke, MD, PhD (1) · Gail Roboz, MD (1) · Jeffrey J. Raizer, MD (1) · Leland Metheny, MD (1) · Omar S Aljitawi, MBBS (1) · Ruben A. Mesa, M.D. (1) · Stefan O Ciurea (1)
P30CA015083 (1), P30CA016672 (1), P30CA043703 (1), P30CA060553 (1)